<DOC>
	<DOCNO>NCT02619877</DOCNO>
	<brief_summary>This phase II single-blinded study evaluate efficacy ALLO-ASC-DFU patient Diabetic Foot Ulcer , compare standard therapy .</brief_summary>
	<brief_title>Clinical Study Evaluate Safety Efficacy ALLO-ASC-DFU Paitents With Diabetic Foot Ulcers</brief_title>
	<detailed_description>ALLO-ASC-DFU hydrogel sheet contain allogenic adipose-derived mesenchymal stem cell . Adipose-derived stem cell anti-inflammatory effect release growth factor vascular endothelial growth factor ( VEGF ) hepatocyte growth factor ( HGF ) , enhance wound heal regeneration new tissue , finally may provide new option treat Diabetic Foot Ulcer .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1 . Subject 18 year 80 year age . 2 . Subject diagnose Type I Type II diabetes , define diabetic foot ulcer presence wind 4 week screen visit . 3 . Ulcer locate foot , ulcer size 1 cm2 25 cm2 . 4 . Ulcer extend dermis , subcutaneous tissue , tendon joint capsule ( Wagner grade 1 2 ) . 5 . Ulcer free necrotic debris . 6 . Subjects adequate circulation ulcer document either : Palpation pulse around ulcer use Doppler exam Ankle Brachial index ( ABI ) value range 0.7 1.3 , Transcutaneous Oxygen Pressure ( TcPO2 ) &gt; 30 mmHg . 7 . Subject able give write informed consent prior study start comply study requirement . 1 . Ulcer nondiabetic pathophysiology . 2 . The ulcer increase decreased size 30 % one week screen visit . 3 . Subject Human Immunodeficiency Virus ( HIV ) positive . 4 . Subjects severe hepatic deficiency . 5 . Subjects glycated hemoglobin A1c ( HbA1c ) level &gt; 15 % . 6 . Subject allergic hypersensitive reaction bovinederived protein fibrin glue . 7 . Subjects require intravenous ( IV ) antibiotic treat index wound infection . 8 . Subjects currently receive dialysis . 9 . Subjects pregnant breastfeeding . 10 . Subjects unwilling use `` effective '' method contraception study . 11 . Current evidence severe infection include pus drainage wind site . 12 . Subjects clinically relevant history alcohol drug abuse . 13 . Subject 's blood sugar &gt; 450 mg/dL postprandial . 14 . Subjects able understand objective study comply study requirement . 15 . Subjects consider significant disease impact study investigator . 16 . Subjects consider suitable study investigator . 17 . Subjects history surgery malignant tumor within last five year ( except carcinoma site ) . 18 . Subjects currently enrol another clinical study within 60 day screen . 19 . Subjects undergone wound treatment cell therapy , dermal substitute , biological therapy within last 30 day . 20 . Subjects receive oral parenteral corticosteroid , immunosuppressive , cytotoxic agent unstable dosage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>